公开(公告)号：US11168123B2

公开(公告)日：2021-11-09

申请号：US16078568

申请日：2017-03-15

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Masashi Shimizu ,  Toshitaka Sato ,  Yoshihisa Arita

IPC: C07K14/475 ,  C12P21/02 ,  C12N9/64 ,  C12N15/09 ,  C12N5/10

Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.

公开(公告)号：US20200341014A1

公开(公告)日：2020-10-29

申请号：US16078557

申请日：2017-03-16

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Mai Kimura ,  Sotaro Motoi ,  Takashi Obara ,  Katsuhiro Moriya ,  Hideaki Ogasawara ,  Yoshihisa Arita ,  Tetsu Kawano

IPC: G01N33/92 ,  C12Q1/6883

Abstract: The present invention provides a method for evaluating the pharmacological action of HGF that utilizes a PD marker in which fluctuation is recognized by administration of hepatocyte growth factor (HGF) in a broader range of subjects. A method for evaluating the pharmacodynamic action of HGF is provided. The aforementioned evaluation method is characterized in that it comprises a step of measuring the ApoA4 level in a biological sample collected from a test subject who was administered HGF. According to the present invention, a kit for evaluating the pharmacodynamic action of HGF comprising an anti-ApoA4 antibody is further provided.

公开(公告)号：US11548926B2

公开(公告)日：2023-01-10

申请号：US16078568

申请日：2017-03-15

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Masashi Shimizu ,  Toshitaka Sato ,  Yoshihisa Arita

IPC: C07K14/475 ,  C12P21/02 ,  C12N9/64 ,  C12N15/09 ,  C12N5/10

Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.

公开(公告)号：US11325960B2

公开(公告)日：2022-05-10

申请号：US16078568

申请日：2017-03-15

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Masashi Shimizu ,  Toshitaka Sato ,  Yoshihisa Arita

IPC: C07K14/475 ,  C12P21/02 ,  C12N9/64 ,  C12N15/09 ,  C12N5/10

Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.

公开(公告)号：US20240218035A1

公开(公告)日：2024-07-04

申请号：US18429738

申请日：2024-02-01

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Masashi Shimizu ,  Toshitaka Sato ,  Yoshihisa Arita

IPC: C07K14/475 ,  C12N5/10 ,  C12N9/64 ,  C12N15/09 ,  C12P21/02

CPC classification number: C07K14/4753 ,  C12N9/64 ,  C12P21/02 ,  C12N5/10 ,  C12N15/09

Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.

公开(公告)号：US20220267393A1

公开(公告)日：2022-08-25

申请号：US17737343

申请日：2022-05-05

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Masashi Shimizu ,  Toshitaka Sato ,  Yoshihisa Arita

IPC: C07K14/475 ,  C12N9/64 ,  C12P21/02

Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.

公开(公告)号：US11466065B2

公开(公告)日：2022-10-11

申请号：US16078568

申请日：2017-03-15

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Masashi Shimizu ,  Toshitaka Sato ,  Yoshihisa Arita

IPC: C07K14/475 ,  C12P21/02 ,  C12N9/64 ,  C12N15/09 ,  C12N5/10

Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.

公开(公告)号：US20190062390A1

公开(公告)日：2019-02-28

申请号：US16078568

申请日：2017-03-15

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Masashi Shimizu ,  Toshitaka Sato ,  Yoshihisa Arita

IPC: C07K14/475 ,  C12P21/02

Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.